UBS Group’s DICE Therapeutics, Inc. Common Stock DICE Stock Holding History

UBS Group’s Portfolio DICE Stock Details DICE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-399,284	Closed	-$18.6M	–	10293
2023 Q2	$18.6M	Buy	399,284 +383,140	+2,373%	+$13.2M	0.01%	1505
2023 Q1	$463K	Buy	16,144 +7,058	+78%	+$209K	﹤0.01%	4755
2022 Q4	$283K	Buy	9,086 +8,963	+7,287%	+$292K	﹤0.01%	5174
2022 Q3	$2K	Buy	+123	New	+$2.24K	﹤0.01%	9850
2022 Q2	–	Sell	-2,059	Closed	-$39K	–	11340
2022 Q1	$39K	Sell	2,059 -2,372	-54%	-$42.3K	﹤0.01%	6749
2021 Q4	$112K	Buy	+4,431	New	+$130K	﹤0.01%	6218

UBS Group's DICE Position: Q3 2023 in Review

UBS Group sold out of DICE Therapeutics, Inc. Common Stock (DICE) in Q3 2023, closing a stake of 399,284 shares — an estimated $18.6M sold.

UBS Group first reported a position in DICE in Q4 2021 and held it in 6 quarters. The position peaked at $18.6M in Q2 2023. 0 funds tracked by Wall St. Rank hold DICE as of Q3 2023.

UBS Group reported no remaining DICE Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
UBS Group sold 399,284 DICE Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $18.6M.
UBS Group first reported a position in DICE Therapeutics, Inc. Common Stock in Q4 2021 and held it in 6 quarters.
UBS Group's DICE Therapeutics, Inc. Common Stock position peaked at $18.6M in Q2 2023.
0 funds tracked by Wall St. Rank held DICE Therapeutics, Inc. Common Stock as of Q3 2023.

Based on UBS Group's 13F filing for Q3 2023, filed 9 Nov 2023.